secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-08-18T23:59:59+00:00
Accession:  0001213900-23-069028
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial sells Purnovate assets to related-party Adovate for $450K cash, 19.9% equity, up to $61M milestones
--------------------------------------------------------------------------------

- Sale of Purnovate business closed June 30; buyer is a related party (former CEO, current director).
- Consideration includes $450K upfront, 19.9% equity in Adovate, low single-digit royalties on net sales.
- Up to ~$11M in development milestones per compound and up to $50M in commercial milestones.
- Pro forma shows a gain of ~$2.5M on balance sheet and $2.05M income from discontinued ops for FY2022.
- Adovate assumed Purnovate trade payables, lease, and contingent liabilities to former Purnovate shareholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023069028/0001213900-23-069028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023069028/ea183898-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-069028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer